{"id":13804,"date":"2021-01-27T01:04:49","date_gmt":"2021-01-27T01:04:49","guid":{"rendered":"https:\/\/clinlabint.com\/?p=13804"},"modified":"2021-01-29T01:22:43","modified_gmt":"2021-01-29T01:22:43","slug":"novigenix-led-consortium-secures-eurostars-funding-to-develop-predictive-immune-checkpoint-inhibitor-test","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/novigenix-led-consortium-secures-eurostars-funding-to-develop-predictive-immune-checkpoint-inhibitor-test\/","title":{"rendered":"Novigenix-led consortium secures Eurostars funding to develop predictive immune checkpoint inhibitor test"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Novigenix-led consortium secures Eurostars funding to develop predictive immune checkpoint inhibitor test<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Novigenix SA Switzerland, a pioneer in immuno-transcriptomics for precision medicine, will lead a consortium, including PamGene International and Radboud University (The Netherlands), to develop a blood based multi-omics test to predict response to immune checkpoint inhibitors in cancer. The consortium has been awarded a grant up to \u20ac1 million under the Eurostars programme.<\/p>\n

<\/p>\n

Immune checkpoint inhibitors (ICIs) have become one of the main treatments for patients with metastatic cancer. Although ICIs are highly effective with durable results in some patients, only a minority respond and benefit from ICIs. Thus, there is a significant unmet medical need for accurate liquid biopsy solutions for selecting patients for ICI therapy.<\/p>\n

The aim of the consortium is to develop a novel in vitro diagnostic (IVD) liquid biopsy test for accurate prediction of response to ICIs, leveraging a unique multi-omics approach of combining mRNA and kinase activity profiling. The biomarker development strategy is based on whole-blood transcriptome and kinomeprofiling technologies. Moreover, the consortium will take advantage of the most advanced machine learning methods to develop and validate the AI based multi-omics signatures.<\/p>\n

The members of consortium have recently generated preliminary promising data for predicting response to anti-PD1 in metastatic urothelial cancer (UC). Novigenix leverages its core competencies in immuno-transcriptomics and provides artificial intelligence solutions for development of multi-omic biomarkers and predictive algorithms.<\/p>\n

Pamgene will provide its unique expertise in Kinome technology, and the group of Dr Niven Mehra, Department of Medical Oncology at Radboud University, will lead a clinical network for prospective collection of biological specimens and data interpretation.<\/p>\n

\u201cThis Eurostars project combines excellent, world-leading science and technologies in a consortium dedicated to developing the first high performance multi-modal liquid biopsy test for the prediction of anti-PD1 response in UC patients,\u201d said Dr Brian Hashemi, executive chairman of Novigenix. \u201cThe high Eurostars review score placed the project in the top 5% of its peers, and we believe its completion can significantly improve personalized ICI therapy for better patient outcomes and health economics.\u201d<\/p>\n<\/div><\/section>
\n